While previous research has implicated E2F1 in the maintenance of GBM malignancy (45), our studies bring to light the fact that E2F1 may only drive proliferation in a subset of GBM cells and tumors, which we can predict using GSEA, and thus targeting E2F1 would only be relevant in these. Here, E2F1 is linked to glioblastoma.